NASDAQ:INDV Indivior Q2 2026 Earnings Report $34.88 -0.81 (-2.27%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$34.88 -0.01 (-0.01%) As of 09/18/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Indivior EPS ResultsActual EPS$5.75Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AIndivior Revenue ResultsActual Revenue$343.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIndivior Announcement DetailsQuarterQ2 2026Date6/30/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsIndivior's Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Indivior Earnings HeadlinesIndivior Terminates Supply Agreement With Reckitt BenckiserSeptember 17 at 12:21 AM | finance.yahoo.comIndivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent On Pending Merger; Stock UpSeptember 17 at 9:19 AM | rttnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 19 at 1:00 AM | The Oxford Club (Ad)Indivior Pharmaceuticals, Inc. Declares Special Cash DividendSeptember 17 at 7:00 AM | globenewswire.comWhy Indivior Pharmaceuticals Inc. (INDV) is a top growth stock for the long termAugust 31, 2026 | msn.comIndivior Pharmaceuticals Inc. (INDV) loses 12.9% in 4 weeks, here's why a trend reversal may be around the cornerAugust 31, 2026 | msn.comSee More Indivior Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Indivior? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indivior and other key companies, straight to your email. Email Address About IndiviorIndivior (NASDAQ:INDV) is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose. The company’s key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose. Indivior also markets other buprenorphine-based treatments and specialty medicines, including products for opioid dependence and schizophrenia-related conditions in selected markets. Indivior was established in 2014 through the demerger of the pharmaceutical business of Reckitt Benckiser Group. The company serves patients and healthcare providers primarily in the United States, as well as in markets across Europe, Canada, Australia and other international regions. Indivior is led by Chief Executive Officer Mark Crossley and is headquartered in Richmond, Virginia.View Indivior ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
